Cullinan Therapeutics, Inc. Common Stock
$20.63
$0.09 (+0.44%)
$20.20Day Range$20.84
Key Statistics
Market Cap
$1.32B
Shares Outstanding
64.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 8, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$20.50
Day High
$20.84
Day Low
$20.20
Volume
825.8K
VWAP
$20.57
Prev Close
$20.54
Transactions
--
Acc. Volume
--
About Cullinan Therapeutics, Inc. Common Stock
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836109 employeesONE MAIN STREET, CAMBRIDGE, MA, 02142617-410-4650IPO Jan 8, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001789972
- Composite FIGI
- BBG00HW2DGQ4
- Share Class FIGI
- BBG00HW2DGR3
- Ticker Root
- CGEM
- SIC Code
- 2836
About Cullinan Therapeutics, Inc. Common Stock (CGEM) Stock
Cullinan Therapeutics, Inc. Common Stock (CGEM) closed the 2026-09-16 session at $20.63, up 0.44% versus the previous close (+0.09). The stock opened at $20.50 and traded between $20.20 and $20.84 during that session. Session trading volume was 826K shares. The volume-weighted average price (VWAP) is $20.57.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Cullinan Therapeutics, Inc. Common Stock has a market capitalization of $1.32 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CGEM is listed on the XNAS exchange. The company employs approximately 109 people. Cullinan Therapeutics, Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2021-01-08.
On this page you can find market CGEM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.